Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Patrick Chalbos"'
Autor:
Antoine Adenis, Thibault Mazard, Julien Fraisse, Patrick Chalbos, Brice Pastor, Ludovic Evesque, Francois Ghiringhelli, Caroline Mollevi, Stéphanie Delaine, Marc Ychou
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
Abstract Background The chemotherapy triplet FOLFOXIRI combined to the anti-VEGF antibody bevacizumab is an option in selected patients with metastatic colorectal cancer. In this setting, RAS-mutated metastatic colorectal cancer do not benefit the sa
Externí odkaz:
https://doaj.org/article/17e448b14f574e0c99aced3091049c7c
Autor:
Antoine Adenis, François Ghiringhelli, Ludovic Gauthier, Thibault Mazard, Ludovic Evesque, Pierre-Luc Etienne, Alexandre Evrard, Patrick Chalbos, Jean-Pierre Bleuse, Diego Tosi, Sophie Gourgou, Marc Ychou
Publikováno v:
Journal of Clinical Oncology. 40:3561-3561
3561 Background: Standard treatment options for RAS-mutated mCRC pts include the combination of bevacizumab with FOLFIRINOX, a three-drug chemotherapy regimen. Unlike bevacizumab, REGO – an oral multi-tyrosine kinase agent - exhibits not only antia
Autor:
Patrick Chalbos, Bernard Guillot, Julie Caron, Fabienne Portales, Catherine Fiess, Marc Ychou, Olivier Dereure, Jacqueline Duffour, Christine Gestin-Boyer, Agnès Garcin, Emmanuelle Samalin, Simon Thezenas
Publikováno v:
European Journal of Cancer. 46:3169-3174
The aim of this study was to measure the inter-observer agreement between two teams of three dermatologists and oncologists in labelling and grading the cetuximab-induced dermatological toxicities from 98 photographs performed in a cohort of 15 patie
Autor:
Antoine Italiano, Fabienne Portales, Marc Ychou, Sylvain Poujol, Patrick Chalbos, Emmanuelle Samalin, Antoine Adenis, Isabelle Solassol, Simon Thezenas, Eric Assenat, Sophie Cousin, Thibault Mazard
Publikováno v:
Journal of Clinical Oncology. 36:e16189-e16189
e16189Background: S-1, an oral fluoropyrimidine, combined with Irinotecan (IRI) or Oxaliplatin (OX) (biweekly schedule) was assessed in Asian populations with acceptable safety profile and efficacy...
Autor:
Patrick Chalbos, Emmanuel Conseiller, Pierre Martineau, Laurent Candeil, Frédéric Bibeau, Franck Molina, Pierre Mazière, C. Bareil, Caroline Fraslon, Virginie Granci, Nicolas Salvetat, Virginie Copois, Caroline Bascoul-Mollevi, Andrew Kramar, Bernard Pau, Maguy Del Rio, Marc Ychou
Publikováno v:
Journal of Biotechnology
Journal of Biotechnology, 2007, 127 (4), pp.549-59. ⟨10.1016/j.jbiotec.2006.07.032⟩
Journal of Biotechnology, Elsevier, 2007, 127 (4), pp.549-59. ⟨10.1016/j.jbiotec.2006.07.032⟩
Journal of Biotechnology, 2007, 127 (4), pp.549-59. ⟨10.1016/j.jbiotec.2006.07.032⟩
Journal of Biotechnology, Elsevier, 2007, 127 (4), pp.549-59. ⟨10.1016/j.jbiotec.2006.07.032⟩
DNA microarray technology enables investigators to measure the expression of several 1000 mRNA species simultaneously in a biological specimen. However, the reliability of the microarray technology to detect transcriptional differences representative
Autor:
Jacqueline Duffour, Patrick Chalbos, Françoise Desseigne, Frédéric Pinguet, Charles Debrigode, Sylvain Poujol, Sophie Gourgou, Laurent Mineur, Marc Ychou, Françoise Bressole
Publikováno v:
Cancer Chemotherapy and Pharmacology. 60:383-389
Irinotecan at 180 mg/m² combined with an infusional 5-fluorouracil/leucovorin (5-FU/LV) regimen (FOLFIRI) is a standard first line therapy for metastatic colorectal cancer (mCRC). This phase II study aimed to assess whether increasing the irinotecan
Autor:
Emmanuel Conseiller, Bernard Pau, Maguy Del Rio, Patrick Chalbos, C. Bareil, Benjamin Leblanc, Nicolas Salvetat, Marc Ychou, Caroline Fraslon, Franck Molina, Virginie Copois, Frédéric Bibeau, Pierre Martineau, Virginie Granci, Caroline Bascoul-Mollevi, Andrew Kramar
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2007, 25 (7), pp.773-80. ⟨10.1200/JCO.2006.07.4187⟩
Journal of Clinical Oncology, 2007, 25 (7), pp.773-80. ⟨10.1200/JCO.2006.07.4187⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2007, 25 (7), pp.773-80. ⟨10.1200/JCO.2006.07.4187⟩
Journal of Clinical Oncology, 2007, 25 (7), pp.773-80. ⟨10.1200/JCO.2006.07.4187⟩
Purpose In patients with advanced colorectal cancer, leucovorin, fluorouracil, and irinotecan (FOLFIRI) is considered as one of the reference first-line treatments. However, only about half of treated patients respond to this regimen, and there is no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5a165b5d5a8016192426e8a771f4b7f
https://www.hal.inserm.fr/inserm-00147002/file/Gene_expression_signature_JCO_Del_Rio.pdf
https://www.hal.inserm.fr/inserm-00147002/file/Gene_expression_signature_JCO_Del_Rio.pdf
Autor:
Céline Gongora, Patrick Chalbos, M. Ychou, Frédéric Bibeau, Pierre Martineau, M. Del Rio, Caroline Bascoul-Mollevi, Andrew Kramar
Publikováno v:
European Journal of Cancer Supplements. 6:64
Autor:
Sophie Gourgou, Françoise Desseigne, Patrick Chalbos, M. Ychou, Laurent Mineur, C. Debrigode, Jacqueline Duffour
Publikováno v:
Journal of Clinical Oncology. 22:3601-3601
3601 Background: The combination of CPT11 at 180 mg/m2 combined with LV5FU2 regimen is one of the standard therapies in first line MCRC. We previously showed (Ychou et al., Cancer Chemother Pharmacol. 2002.) a safe dose effect activity of CPT11 in mo